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The EuroRotaNet surveillance network has con-
ducted rotavirus genotype surveillance since 2007 
in 16 European countries. Using epidemiological and 
microbiological data from 39,786 genotyped rotavi-
rus-positive specimens collected between September 
2007 and August 2013, we assessed genotype dis-
tribution and age distribution of rotavirus gastroen-
teritis (RVGE) cases in and out of peak season in 12 
countries which were yet to implement routine rota-
virus vaccination. In multinomial multivariate logis-
tic regression, adjusting for year, country and age, 
the odds of infection caused by genotype-constel-
lation 2 DS-1-like stains (adjusted multinomial odds 
ratio (aM-OR) = 1.25; 95% confidence interval (CI): 
1.13–1.37; p < 0.001), mixed or untypable genotypes 
(aM-OR = 1.55; 95% CI: 1.40–1.72; p < 0.001) and less 
common genotypes (aM-OR = 2.11; 95% CI:1.78–2.51; 
p < 0.001) increased out of season relative to G1P[8]. 
Age varied significantly between seasons; the pro-
portion of RVGE cases younger than 12 months in the 
United Kingdom increased from 34% in season to 39% 
out of season (aM-OR = 1.66; 95% CI: 1.20–2.30), and 
the proportion five years and older increased from 9% 
in season to 17% out of season (aM-OR = 2.53; 95% CI: 
1.67–3.82). This study provides further understanding 
of the rotavirus ecology before vaccine introduction, 
which will help interpret epidemiological changes in 
countries introducing or expanding rotavirus vaccina-
tion programmes.
Introduction
Rotavirus is the most common cause of acute gas-
troenteritis in children under five years of age, caus-
ing an estimated 450,000 deaths per year worldwide, 
with over 90% of deaths occurring in developing coun-
tries [1]. In high-income countries, rotavirus infections 
result in few deaths but still constitute a substantial 
healthcare burden and can cause severe morbidity 
[2,3]. There are eight groups of rotaviruses defined by 
the middle capsid antigen [4]; the majority of rotavirus 
gastroenteritis (RVGE) in humans is caused by group A 
rotaviruses.
Group A rotavirus genotypes are typically further clas-
sified into G and P types, based on sequence diver-
sity of the genes encoding the outer viral proteins VP7 
(glycoprotein) and VP4 (protease-sensitive protein), 
respectively [5]. Furthermore, whole genome sequenc-
ing has allowed rotavirus strains to be classified into 
genotype constellations based on a common genomic 
backbone in which the genotypes of nine of the 11 
genes are conserved, while G and P types may vary. 
Human rotaviruses typically belong to the Wa-like or 
the DS-1-like genotype constellations [6].
Two oral vaccines, the two-dose monovalent vaccine 
(Rotarix, GlaxoSmithKline Biologicals, Belgium) and 
the three-dose pentavalent vaccine (RotaTeq, Merck, 
United States), have been introduced into a number 
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of countries worldwide since their licensure in 2006. 
Eight European Union countries have included rotavi-
rus vaccines in their routine childhood immunisation 
schedules and several other countries make the vac-
cine available through state or private sector health-
care [7].
Monitoring the emergence of novel rotavirus genotypes 
and the potential for genotype replacement and genetic 
drift is an essential activity of surveillance. This has 
become more important since the introduction of rota-
virus vaccination, as there was some early evidence in 
countries such as Australia, Brazil and Belgium that 
vaccination may have contributed to changes in the 
predominant genotypes, although these changes may 
also have been the result of natural variation [8,9]. The 
EuroRotaNet surveillance network, established in 2007 
and including 16 countries, has been monitoring rotavi-
rus genotype diversity and year-to-year genotype fluc-
tuations across Europe for eight years [10,11]. Critically, 
the availability of substantial genotyping and epide-
miological data for EuroRotaNet countries provides a 
baseline for genotype diversity and the epidemiology 
of RVGE cases before vaccine introduction. Therefore, 
while year-to-year differences in genotypes in Europe 
have been described previously [11,12], this paper 
reports in-peak season and out-of-season variation 
of rotavirus genotypes and age of infection for 12 
European countries before the introduction of routine 
vaccination.
Methods
EuroRotaNet
The EuroRotaNet surveillance network was initiated 
in 2007 and includes 16 countries: Austria, Belgium, 
Bulgaria, Denmark, Finland, France, Germany, Greece, 
Hungary, Italy, Lithuania, the Netherlands, Slovenia, 
Spain, Sweden and the United Kingdom (UK). Data 
from typed rotavirus-positive faecal specimens is 
linked to case epidemiological information by par-
ticipating laboratories and uploaded to a secure web-
accessible EuroRotaNet database. The data contained 
in the EuroRotaNet dataset has been described previ-
ously [10,11].
Figure 1
Number of rotavirus specimens typed per week by country and surveillance year, 12 European Union countries, September 
2007–August 2013 (n = 39,786) 
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Study area
Twelve countries from EuroRotaNet were included in 
the study. Data from Austria, Belgium, Finland and 
Germany were excluded from the analysis because 
rotavirus vaccination was either routine or widespread 
(> 35%) in these countries during the study period [13]. 
Samples
Study samples included rotavirus-positive faecal sam-
ples from mostly sporadic gastroenteritis cases; if 
associated with outbreaks, only a single sample per 
outbreak was submitted for routine diagnostic test-
ing at sentinel participating EuroRotaNet laboratories 
and typed using standardised G and P typing methods 
[12,14]. Diagnostic testing protocols varied between 
countries [12,14].
Data and survey
Details on case age, sex and country, specimen collec-
tion date and rotavirus genotyping results for a total 
of six rotavirus seasons spanning September 2007 to 
August 2013 were included in this study. Greece joined 
EuroRotaNet in 2008; therefore, for Greece only five 
rotavirus seasons were included in the analysis, span-
ning September 2008 to August 2013.
Data for each of the 12 countries were pooled for the 
study period. Age groups of cases (0–11 months, 12–23 
months, 2–4 years and ≥ 5 years) were constructed 
using date of birth and date of specimen collection. 
Genotypes were categorised as ‘G1P[8]’, ‘genotype-
constellation 1 (Wa-like: G3P[8], G4P[8], G9P[8] and 
G12 P[8])’, ‘genotype-constellation 2 (DS-1-like: G2P[4] 
and G8P[4])’, ‘mixed and untypable’, and less common 
genotypes were combined under the category ‘other’. 
Although G1P[8] is considered part of genotype-con-
stellation 1 (Wa-like), we grouped it separately because 
of its high prevalence across Europe [12]. A derived 
binary variable was constructed to denote weeks within 
a country’s peak season and non-peak rotavirus sea-
sons, and was developed by pooling country-specific 
weekly specimen frequencies over the study period 
to calculate the overall median weekly specimen fre-
quency. We used the country-specific median value as 
a threshold for defining the start and end of the peak 
rotavirus season over the study period. Consequently, 
a weekly specimen frequency greater than or equal to 
the median identified weeks as in-season and a weekly 
frequency less than the median identified weeks as 
out-of-season. A consecutive period of two weeks 
Figure 2
Number of rotavirus specimens collected in season and out of season, by country, 12 European Union countries, September 
2007–August 2013 (n = 39,786)
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above or below the threshold was required to identify 
the beginning and end of a season to ensure season 
identification was robust to stochastic fluctuations.
To identify additional detail on country-specific in-
season and out-of-season testing practices, we con-
structed a brief semi-structured questionnaire using 
SelectSurvey.Net [15]. The questionnaire was distrib-
uted to EuroRotaNet collaborators by email in July 2014. 
The questionnaire included questions on duration of 
rotavirus season within the country, typical diagnostic 
testing practices, identification of changes to testing 
practices during the study period (including dates of 
any changes), positivity rate and proportion of posi-
tive samples typed. The questionnaire also asked for 
details on any age restrictions to testing or other algo-
rithms that may have influenced testing and whether 
these may have changed between rotavirus seasons.
Statistical analysis
Models relating genotypes and age of cases to season
To investigate differences in circulating genotypes and 
age of cases out of season vs in season, we fitted a 
series of mixed-effect multinomial logistic regression 
models with the two main outcomes: genotype group 
and age group of cases. Model fitting was based on 
variables identified a priori and used categorical vari-
ables for genotype group (reference group: G1P[8]), age 
group of the case (reference group: 12–23-month-olds), 
surveillance year (September to August) and country, 
and the binary season indicator was the covariate term 
of interest. The following adjusted models were then 
fit:
Genotype full model (model 1): genotype as the out-
come variable; season, age group of case and surveil-
lance year as covariates; and a random intercept for 
country.
Figure 3
Country-stratified crude and adjusted multinomial odds ratios for genotypes occurring out of season vs in season (model 2; 
n = 39,786) and for age group (model 4; n = 39,007), 12 European Union countries, September 2007–August 2013
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Genotype country-stratified model (model 2): model 
1 but without a random intercept for country; effec-
tively a series of country-specific multinomial logistic 
regressions.
Age group full model (model 3): age group of cases as 
the outcome variable; season, genotype and surveil-
lance year as covariates; and a random intercept for 
country.
Age group country-stratified model (model 4): model 
3 but without a random intercept for country; effec-
tively a series of country-specific multinomial logistic 
regressions.
Each model was initially run as a univariate analy-
sis including only the binary season indicator as the 
covariate term of interest. Multinomial odds ratios 
(M-OR; also referred to as RR ratios), 95% confidence 
intervals (CI) and the associated p values for season 
were calculated from the Wald test. Results were con-
sidered significant at p < 0.05. In supplementary anal-
yses, mixed-effects multinomial logistic regression 
investigated the relationship between age group and 
genotype group regardless of season, therefore model 
1 was re-run excluding season as a covariate (model 5).
Strain diversity
Rotavirus genotype diversity in the 12 European coun-
tries studied was compared using two established 
biodiversity indices, Simpson’s index of diversity and 
Shannon’s index [16]. Simpson’s index of diversity (D) 
represents the probability that two randomly chosen 
rotavirus genotypes will have different G and P types 
and is calculated as 1 − λ, where λ = Σ(pi
2) and pi is the 
proportional abundance of a genotype i. Shannon’s 
index (H’) quantifies the uncertainty in predicting the 
rotavirus genotype identity of an individual sample 
that is taken at random from the dataset and is calcu-
lated as H’ = − Σ(pi × ln(pi)). Confidence intervals were 
estimated using bootstrap resampling methodology 
and differences in season and out of season were com-
pared for each country.
United Kingdom representativeness test
Linear regression was used to assess the representa-
tiveness of the seasonality of genotyped rotavirus data 
in comparison to all confirmed laboratory reports of 
rotavirus infection in the UK. The regression takes the 
form, Y = α + β1X1 + β2X2  + ε, where Y is the number of 
confirmed laboratory reports of rotavirus infection, X 
represents the covariates (number of genotyped rotavi-
rus specimens and month of specimen), α is the inter-
cept term and ε represents the error term.
Figure 4
Rotavirus genotype diversity measured using Shannon’s index and Simpson’s index of diversity, with 95% confidence 
intervals, by country, 12 European Union countries, pooled September 2007–August 2013 (n = 39,786)
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All data handling and statistical analyses were per-
formed using R Version 3.1.2. and Stata Version 14 
[17,18]. The R packages ‘Vegan’ and ‘boot’ were used 
for analysis of genotype biodiversity [19,20]. Data 
tables are available through the EuroRotaNet website 
or available on request from the authors [10].
Results
Descriptive statistics
A total of 39,786 rotavirus-positive specimens from 
12 countries were typed between September 2007 
and August 2013. Rotavirus seasonality for genotyped 
rotavirus-positive specimens was variable across the 
countries studied (Figure 1). In the UK, the peak of the 
rotavirus season was well defined every year, typically 
occurring between weeks 10 and 12. The representa-
tiveness test for the UK confirmed that the seasonal 
pattern of the typed rotavirus specimens was repre-
sentative of laboratory-confirmed rotavirus cases in 
the UK (adjusted R2 = 0.75). Table 1 shows the total 
number of typed specimens for each country, the num-
ber in season and out of season, and the number of 
weeks per year classified as in season. The proportion 
of specimens referred for typing that were collected in 
season ranged from 68% in Greece to 95% in the UK.
The predominant genotype overall was G1P[8], repre-
senting 48% of the specimens included in the analysis 
(range: 24% in Bulgaria to 63% in France). G1P[8] pre-
dominated in all countries except Greece and Bulgaria 
where the predominant genotypes were G4P[8] and 
G2P[4], respectively (Table 2). Children younger than 
five years contributed 93% of the specimens (range: 
77% in Denmark to 97% in Bulgaria, France and Italy).
It is difficult to distinguish aberrant events due to the 
data’s stochastic nature (Figure 1). However, some can 
been explained by outbreaks of particular genotypes. 
For instance in Spain, the increased incidence during 
the 2011/12 surveillance year was due to an outbreak 
of G12P[8] in the north-eastern province of Gipuzkoa.
Genotypes in season and between rotavirus 
seasons
Across all countries studied, when adjusting for country, 
surveillance year and age group, the adjusted multino-
mial odds ratio (aM-OR) of infection caused by strains 
with DS-1-like genotype-constellation (aM-OR = 1.25; 
95% CI: 1.13–1.37; p < 0.001), mixed or untypable geno-
types (aM-OR = 1.55; 95% CI: 1.40–1.72; p < 0.001) and 
less common genotypes (group: ‘other’; aM-OR = 2.11; 
95% CI: 1.78–2.51; p < 0.001) increased out of season 
relative to G1P[8], while infection caused by strains 
with Wa-like genotype constellation declined (aM-
OR = 0.93; 95% CI: 0.86–1.00; p = 0.04) (model 1).
In country-stratified analyses (model 2), the propor-
tional distribution of rotavirus genotypes varied by 
country (Figure 2). There were significant differences 
in the proportional representation of genotypes from 
specimens collected in season and out of season in 
10 of the 12 countries studied. In these 10 counties, 
out-of-season specimens were more likely to belong 
to a less common genotype (group: ‘other’) than 
specimens collected in season (Figure 3). However, 
this was only significant in eight countries, with the 
highest aM-OR observed in Spain (aM-OR = 8.18; 
95% CI: 4.57–14.64) and Slovenia (aM-OR = 4.49; 
95% CI: 1.56–12.88). DS-1-like genotypes were sig-
nificantly more likely to occur out of season in 
Country Total specimens In season Out of season In-season weeks  (calendar weeks)
Number Number % Number % Number
Bulgaria 2,627 2,296 87 331 13 31–17
Denmark 1,392 1,192 86 200 14 1–26
France 5,044 4,584 91 460 9 48–21
Greecea 2,115 1,447 68 668 32 50–21
Hungary 2,263 1,835 81 428 19 1–23
Italy 6,955 5,685 82 1,270 18 48–22
Lithuania 2,990 2,582 86 408 14 49–23
The Netherlands 2,508 2,346 94 162 6 48–22
Slovenia 2,779 2,272 82 507 18 1–22
Spain 4,609 4,227 92 382 8 47–21
Sweden 1,232 1,030 84 202 16 1–20
United Kingdom 5,272 5,014 95 258 5 1–25
Total 39,786 34,510 87 5,276 13 NA 
NA: not applicable.
a Data between September 2008 and August 2013.
Table 1
Number of rotavirus specimens collected in season and out of season, by country, 12 European Union countries, September 
2007–August 2013 (n = 39,786)
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Bulgaria (aM-OR = 1.98; 95% CI: 1.35–2.90), France 
(aM-OR = 1.67; 95% CI: 1.18–2.37), Italy (aM-OR = 1.94; 
95% CI: 1.56–2.42), the Netherlands (aM-OR = 2.79; 
95% CI: 1.65–4.71), Slovenia (aM-OR = 1.61; 95% CI: 
1.18–2.18) and the UK (aM-OR = 1.90; 99CIs: 1.25–
2.90), whereas they were less likely to occur out of sea-
son in Spain (aM-OR = 0.32; 95% CI: 0.19–0.57) and 
Greece (aM-OR = 0.41; 95% CI: 0.29–0.59). Untypable 
and mixed genotypes had significantly higher propor-
tional representation out of season in Bulgaria (aM-
OR = 2.47; 95% CI: 1.63–3.73), Italy (aM-OR = 1.32; 
95% CI: 1.10–1.60), the Netherlands (aM-OR = 2.57; 
95% CI: 1.53–4.29), Spain (aM-OR = 2.14; 95% CI: 1.55–
2.98) and the UK (aM-OR = 4.13; 95% CI: 2.59–6.57). 
Only the UK (aM-OR = 1.38; 95% CI: 1.00–1.90) showed 
a significant change in the proportional representation 
of other genotype-constellation 1 (Wa-like) genotypes 
out of season compared with in season. Although 
Sweden and Denmark were the only two countries that 
did not show significant changes in genotype distribu-
tion out of season compared with in season, they had 
very different genotype distributions (Table 2).
Age of cases in season and out of season
Across all countries studied, when adjusting for coun-
try, surveillance year and genotype, the aM-OR of 
infection in two- to four-year-olds (aM-OR = 1.13; 95% 
CI: 1.04–1.22; p < 0.01) and in those five years and older 
(aM-OR = 1.13; 95% CI: 1.00–1.27; p = 0.04) increased 
out of season relative to the younger children 12–23 
months of age, while declining in those younger than 12 
months (aM-OR = 0.92; 95% CI: 0.85–0.99; p = 0.03) 
(model 3). Country-stratified analyses (model 4) 
showed that when adjusting for genotype and surveil-
lance year, half of the countries experienced significant 
variation in the age group of cases out of season as 
compared with in season (Figure 3). Cases five years 
and older constituted a higher proportion of the out-of-
season than of the in-season cases in Greece, Italy, the 
Netherlands, Slovenia, Spain, Sweden and the UK. This 
difference was only significant in Spain (aM-OR = 1.76; 
95% CI: 1.11–2.81) and the UK (aM-OR = 2.53; 95% CI: 
1.67–3.82). In France (aM-OR = 1.51; 95% CI: 1.12–2.04) 
and the Netherlands (aM-OR = 1.79; 95% CI: 1.13–
2.82), two- to four-year olds were significantly more 
commonly represented out of season compared with 
in season. Lithuania had significantly smaller propor-
tions of cases 0–11 months of age (aM-OR = 0.56; 95% 
CI: 0.39–0.78) in season compared with out of season, 
whereas Greece (aM-OR = 1.36; 95% CI: 1.07–1.73) and 
the UK (aM-OR = 1.66; 95% CI: 1.20–2.30) had a sig-
nificantly higher proportion of cases younger than 12 
months out of season compared with in season.
Relationship between age of cases and genotype 
group
There was a significant association between increas-
ing age and the genotypes causing disease regardless 
of season. Those five years and older were more likely 
to be infected with non-G1P[8] genotypes than those 
younger than five years (model 5). This was most 
pronounced in the DS-1-like genotype-constellation 
(aM-OR = 2.56; 95% CI: 2.27–2.90; p < 0.001), but also 
significant for mixed or untypable genotypes (aM-
OR = 1.92; 95% CI: 1.65–2.23; p < 0.001), less com-
mon genotypes (group: ‘other’) (aM-OR 2.32; 95% CI: 
1.79–3.02; p < 0.001) and Wa-like genotype constella-
tions (aM-OR = 1.15; 95% CI: 1.04–1.27; p < 0.01). The 
0–11-months-old infants were also more likely than the 
reference group (12–23-month-olds) to be infected with 
mixed or untypable genotypes (aM-OR = 1.23; 95% 
CI: 1.11–1.35; p < 0.001) and less common genotypes 
(group: ‘other’) (aM-OR = 1.30; 95% CI: 1.08–1.56; 
p < 0.01)
Genotype diversity
Sweden and France had the lowest genotype diversity 
and Bulgaria the highest (Figure 4). Age group analysis 
showed that genotype diversity was highest in the age 
group five years and older in six of 12 countries based 
on Shannon’s index and in eight of 12 countries based 
on Simpson’s index of diversity. When cases five years 
and older were compared with the reference category of 
12–23-month-olds, diversity was significantly higher in 
Shannon’s index, Simpson’s index of diversity or both 
indices in Denmark (H’: p = 0.021/D: p = 0.585), Italy (H’: 
p < 0.001/D: p < 0.001), the Netherlands (H’: p = 0.192/D: 
p = 0.003), Sweden (H’: p < 0.001/D: p < 0.001) and the 
UK (H’: p < 0.001/D: p < 0.001). When comparing geno-
type diversity in season with out-of-season genotype 
diversity, only Italy and the UK showed significant dif-
ferences in genotype diversity. Both Shannon’s index 
and Simpson’s index of diversity showed significantly 
higher genotype diversity out of season in Italy (H’: 
p = 0.012/D: p < 0.001) whereas only Simpson’s index of 
diversity indicated significantly higher genotype diver-
sity out of season in the UK (H’: p = 0.098/D: p = 0.003).
Survey
All countries responded to the survey. Only Hungary 
indicated that they had reporting laboratories which 
did not test for rotavirus all year round. There was lit-
tle variation in the temporal definition of the peak rota-
virus season between the questionnaire responses 
and the statistical coding specified in the Methods 
chapter. The exceptions were Bulgaria and Denmark. 
The questionnaire response for Bulgaria specified no 
seasonality, whereas we identified weeks 31 to 17 for 
this analysis. For Denmark, the questionnaire response 
specified peak rotavirus season as March to June, 
while for the analysis, we defined it as weeks 1 to 26 
(i.e. beginning in January).
Diagnostic tests used included enzyme-linked immuno-
sorbent assay (ELISA), dual adenovirus/rotavirus rapid 
immunochromatographic tests (RIT), real-time RT-PCR, 
single rotavirus RIT, and electron microscopy. Dual 
RIT (9/12 responses) and ELISA (8/12 responses) were 
the most common tests. During the time period stud-
ied, it was reported that one laboratory in France had 
changed testing from latex agglutination to Dual RIT, 
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and laboratories in four other countries had changed 
from ELISA to real-time RT-PCR or increased its use.
Age testing policies were variable across countries. 
Italy, Spain and the UK specified that they routinely 
test only children younger than five years, while other 
countries either included older children or tested all 
ages. Only one laboratory in France was identified as 
changing age group testing polices out of season. This 
laboratory specified that it changed from testing all 
ages to testing immunocompromised cases and chil-
dren younger than five years only. In addition, a vari-
ety of factors were reported as influencing decision to 
test, but clinician request was selected in every survey 
response. Other common factors influencing decision 
to test included nosocomial outbreaks of acute gas-
troenteritis in a paediatric ward (10/12 responses) and 
diarrhoeal outbreaks in a nursery (8/12 responses). 
Apart from the aforementioned laboratory in France, 
respondents indicated that factors influencing testing 
for rotavirus were the same in season as out of season, 
and all countries stated that their decision to genotype 
did not vary in season and out of season.
Discussion
Significant differences in the circulating rotavirus 
genotypes in season compared with out of season 
were observed across the countries studied. Genotype 
G1P[8] was dominant in season but this dominance 
declined out of season in most countries, whereas the 
proportion of other less abundant genotypes increased 
out of season. Other than the dominance of G1P[8] in 
most countries, there was little consistency in geno-
type distribution across countries studied, highlighted 
by the country-to-country variation in genotype diver-
sity and relative genotype dominance. For instance in 
Bulgaria, no genotype was identified as dominant, and 
the survey results further elucidated that Bulgaria does 
not appear to have a well-defined rotavirus season.
The analysis also showed that there were clear sea-
sonal differences in the age distribution among rotavi-
rus cases out of season vs in season. These differences 
were not consistent across all the countries studied. 
Generally, the proportion of cases five years and older 
increased out of season and in most countries, geno-
types found in cases aged five years and older were 
more diverse than genotypes identified among younger 
age groups regardless of season. Relative to younger 
cases, cases aged at least five years were more likely 
to be infected with a non-G1P[8] genotype, in particular 
genotypes from the DS-1-like genotype constellation.
The relative decline of G1P[8] genotypes out of sea-
son is common in European countries and by defini-
tion coincides with a flattening of incidence, similar to 
countries with smoother incidence throughout the year, 
such as Bulgaria, where no single genotype is domi-
nant. This pattern is also reflected in observations 
from countries which have introduced rotavirus vac-
cination, reinforcing the importance of understanding 
the pre-vaccine ecology of rotavirus infection across 
Europe for interpreting changes in rotavirus genotype 
distribution, seasonality and age of infection after vac-
cine introduction [21–24].
Seasonal and age group differences in the distribution 
of rotavirus genotypes may be driven by differential 
virus fitness among susceptible and partially immune 
hosts. Younger children, who are more susceptible, 
may be preferentially infected by the G1P[8] genotype, 
which given its predominance in most countries may 
be better adapted to the host or to transmission. The 
out-of-season decline in G1P[8] dominance may then 
be driven by the accumulation of homotypic immunity 
to G1P[8] in the community during the rotavirus season, 
reducing the number of susceptible hosts out of season 
and enabling the potentially less fit non-G1P[8] geno-
types to infect those who have homotypic immunity 
from previous exposure to G1P[8] (24–60-month-olds 
may only have partial protection due to limited number 
of exposures) and older individuals infected with other 
genotypes to which cross-protection may be incom-
plete [25,26]. Indeed, a Mexican study showed that 
natural rotavirus infection reduces host susceptibility 
after each infection and that secondary infections are 
more likely to be caused by a different genotype than 
the one causing the first infection [25]. Furthermore, 
this explanation may be consistent with previous find-
ings in which birth cohort effects were identified as 
potential drivers for differences in seasonality across 
the United States (US) [27].
Such differences between heterotypic and homotypic 
protection conferred by the dominant G1P[8] genotype 
support results from vaccine efficacy and observa-
tional studies of the monovalent Rotarix vaccine, which 
show that although the vaccine does protect against 
completely heterologous genotypes (e.g. G2P[4]), it 
may do so to a lesser extent [28–31].
The analysis also showed that mixed and untypable 
genotypes proportionally increased in a number of 
countries out of season. The types available for par-
tially typed rotaviruses (G or P type unobtainable) 
appear to be representative of the more commonly 
found types (typically G1 or P[8]). Insufficient sensitiv-
ity of the typing procedures is the most likely cause for 
the typing failures [32]. These samples may, therefore, 
contain lower viral loads, which are likely to be associ-
ated with infections in previously exposed individuals 
with partial protection and/or subclinical infections.
Therefore, a plausible explanation for the increase in 
the proportional representation of older children and 
adults and of mixed and untypable genotypes out of 
season might be the accidental detection of an (asymp-
tomatic) rotavirus infection in previously exposed indi-
viduals protected from severe RVGE, coinciding with 
infection by another pathogen causing gastrointes-
tinal symptoms that has peak incidence in the sum-
mer months, such as some gastrointestinal bacterial 
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pathogens. This could be supported by a study in the 
US that found that in adults admitted to hospital with 
diarrhoea, rotavirus was as commonly detected as 
bacterial gastrointestinal pathogens [33]. Furthermore, 
pre-vaccine studies suggest that there are high symp-
tomatic and asymptomatic infection rates in adults 
regardless of epidemic season and that re-infection 
in adults persists across the year, which may suggest 
that older children and adults may be a reservoir from 
which the winter/spring paediatric epidemic emerges 
[34–36].
Our findings also suggest rapid genotype cycling from 
in-season to out-of-season periods and, as noted by 
Pitzer et al. [26], this could be caused by relatively 
stronger homotypic immunity than heterotypic immu-
nity in the population, which renders the less com-
mon genotypes increased fitness, permitting them 
to persist in the population [26,37]. Moreover, age 
increases among RVGE cases as the predominant gen-
otype declines, and the rapid cycling to less common 
genotypes out of season may explain the proportional 
increase in two- to four-year-olds and those five years 
and older seen in our analysis out of season [26,27]. 
However, an increase in those five years and older out 
of season may also be influenced by delayed trans-
mission to this group because of mixing and contact 
patterns in younger children and infants. Additionally, 
the change to older age groups and less common gen-
otypes out of season could potentially be related to 
importations associated with travel.
Interpretation of the proportional increase in speci-
mens from those five years and older is, however, com-
plicated by testing practices. The survey suggests that 
laboratories in some countries routinely test for rotavi-
rus only in children younger than five years or, in some 
cases, those younger than 18 years, while limited test-
ing occurs in older age groups. However, only one labo-
ratory among the study countries reported changes 
in either age-specific testing procedures or clinician 
requests in season compared with out of season. Also, 
specifically in the UK, published guidance suggests a 
consistent testing algorithm all year, indicating that the 
reported variation in age of infection is representative 
[38].
Unfortunately, there is no apparent explanation for 
increases in the proportion of rotavirus-positive 
infants younger than 12 months out of season in Greece 
and the UK and for the decline in Lithuania. Findings 
are unlikely to be explained by seasonal birth rates 
as birth rate seasonality is similar in all the countries 
studied, suggesting that other factors, such as low het-
erotypic immunity conferred by previous infection, may 
be responsible [39].
We have described a number of potential hypotheses 
that may contribute to the observed differences in 
genotype and age distribution in season and out of 
season. However, we recognise this is not exhaustive 
and there may be other plausible hypotheses.
Strengths and limitations
Our analysis benefited from using an established sur-
veillance system that has achieved consistency over a 
number of years. We supplemented our understanding 
of these data with a network-wide survey of testing 
practices. Nevertheless, there are limitations. Firstly, 
the sample size of rotavirus-positive samples typed was 
calculated based on detecting genotypes with a preva-
lence of at least 1% and, depending upon the country 
population size and estimated rates of rotavirus infec-
tion, are therefore not representative of the incidence 
of RVGE [11]. Secondly, it is unknown how many sam-
ples are referred for rotavirus diagnosis or how many 
are positive in routine diagnostic laboratories given 
that rotavirus is not a notifiable disease in many of the 
countries studied. For this reason we were unable to 
provide the proportion of positive samples each coun-
try submits for genotyping. Consequently we could not 
quantify the effect of sampling bias on out-of-season 
increases in less common genotypes, and the smaller 
number of cases out of season means that we must be 
aware of random variation when considering the find-
ings. However, the study design helped to increase 
precision by pooling data over a number of seasons. 
Thirdly, data completeness of sex in the EuroRotaNet 
database was inconsistent across the countries stud-
ied. Previous analysis of EuroRotaNet data has shown 
no differences in genotype distribution between the 
sexes [11]. For these reasons sex was excluded from our 
models. Fourthly, the survey has shown that diagnos-
tic procedures can vary slightly between countries and 
that a small number of laboratories have changed test-
ing practices during the study period, which may have 
influenced the number of detected cases. However, a 
study in the UK found no association between number 
of laboratory reports and proportion of cases diag-
nosed by each diagnostic method [40]. Fifthly, even 
though countries included in the study had either low 
vaccination coverage (< 35%) or total absence of rou-
tine rotavirus vaccination [13], we have been unable to 
account for the effect of low-level vaccination in coun-
tries in which vaccine is available in regions and/or in 
the private health care sector, or the effect of routine 
vaccination in neighbouring countries on our findings. 
Finally, it is important to acknowledge that EuroRotaNet 
data are likely to be representative only of moderate to 
severe cases because in many countries, rotavirus is 
not a notifiable disease and because symptoms often 
resolve without healthcare contact.
Conclusions
This study shows that rotavirus genotype distribution 
in Europe is variable and that most countries included 
in this study experience variation in genotypes typed 
from specimens collected during the peak rotavirus 
season compared with the out-of-season periods. 
Changes in age of infection between peak rotavirus 
season and out-of-peak season may be due to lower 
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cross-protection against heterotypic genotypes. These 
findings raise several questions about the genotype 
reservoirs and genotype persistence that may help 
direct future research to understand the temporal vari-
ability in the environment and in hosts. In addition, the 
true burden and epidemiology of rotavirus infections in 
adults and older children are not well understood due 
to age-exclusive testing policies, but the study further 
indicates that this could be critical to understanding 
re-infection and transmission that persists to re-ignite 
the epidemic season each year. 
Finally, of the countries studied here, the UK has since 
introduced rotavirus vaccination into the childhood 
immunisation schedule. Critically, this work provides 
important pre-vaccine ecological data for the UK and 
other European countries introducing or expanding 
rotavirus vaccination programmes. 
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